Generic placeholder image

Current Topics in Medicinal Chemistry


ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Research Advances in the Treatment of Melanoma by Treat Melanoma

Author(s): Can Liu, Si-Qi He, Xiao-Qing Chen, Hui-Qing Xie, Yong Chen, Rui Liu, Ke Cao and Jian-Da Zhou

Volume 16, Issue 2, 2016

Page: [242 - 250] Pages: 9

DOI: 10.2174/1568026615666150812121439

Price: $65


Melanoma is a highly malignant tumor. Prognoses of melanoma patients are often unsatisfactory due to poor operational and chemoradiational efficacy. Recently, researches for melanoma treatment have found multipeptide vaccines a favorite and possible breakthrough as they are stable in chemical property and easy to be synthesized, have no carcinogenecity and dispense with virus vector. Studies have shown that the immunogenicity of multipeptide vaccines could be enhanced by use of immunoadjuvants, joining dendritic cells (DCs), full-length or epitope-superposited antigen peptides, costimulatory molecules and cellpenetrating peptides fusion, thereby improving anti-tumor effect. Certain achievements have been obtained in clinical treatment of melanoma by multipeptide vaccines, but problems including poor immunogenicity and human leukocyte antigen (HLA) phenotype restriction may require further study.

Keywords: Immunogenicity, Melanoma, Multipeptide vaccines, Melanoma-Associated protein 100, Survivin, Immune adjuvants.

« Previous
Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy